arrow
I

Isabelle Fleury

Université Laval
H指数:21
被引数:5,930

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study

利萨库特根马拉鲁塞尔在复发或难治性边缘区淋巴瘤患者中的应用(TRANSCEND FL):一项全球、多队列、单臂、II期研究的主要分析结果

2026-02-120
PRE
Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders
2026-01-200
OAAI
Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

同种异基因造血细胞移植在新型细胞疗法时代治疗B细胞淋巴瘤中的应用:来自一家三级加拿大中心的经验

2025-05-200
OA
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病后基于维尼托克的治疗效果: 一项国际真实世界研究

2024-12-190
OAAI
Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

异基因造血干细胞移植在新型细胞疗法时代中的应用:来自一家三级加拿大中心的经验

BLOOD
IF23.1
2024-11-050
PRE
Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

利索卡巴肽马瑞克塞尔(liso-cel)在复发或难治性(R/R)滤泡性淋巴瘤(FL)患者(pts)中的2年随访:超越FL研究

BLOOD
IF23.1
2024-11-050
PRE
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study (JUL, 10.1038/s41591-024-02986-9, 2024)
2024-07-094
OAAI
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
2024-06-039
OAAI
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (vol 102, pg 1773, 2023)
2023-07-112
OAAI
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

RE-MIND2: 基于复发/难治性弥漫性大b细胞淋巴瘤患者的真实数据,他法他单抗联合来那度胺与polatuzumab维多汀/苯达莫司汀/利妥昔单抗 (pola-br),car-t疗法和来那度胺/利妥昔单抗 (R2) 的疗效比较

2023-05-1213
OAAI
Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge
2023-01-015
OAAI